Using AI to predict Parkinson's risk in patients with REM sleep behavior disorder
Artificial Intelligence on Molecular Imaging to Predict the Risks of Parkinson's Disease for Patients With Rapid Eye Movement Sleep Behavior Disorder
This study is testing if using artificial intelligence to analyze brain scans can help identify people with REM sleep behavior disorder who are at risk of developing Parkinson's disease.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Insel Gruppe AG, University Hospital Bern Academic / other |
| Locations | 1 site (Bern) |
| Trial ID | NCT06629207 on ClinicalTrials.gov |
What this trial studies
This study aims to document the progression of REM sleep behavior disorder (RBD) and identify clinical and imaging biomarkers that may indicate the risk of developing Parkinson's disease and related conditions. Participants will undergo clinical evaluations and two imaging procedures, including PET/CT and MRI, to gather data. The study utilizes artificial intelligence to analyze imaging results and develop predictive models for patient stratification based on their risk of conversion to a-synucleinopathy disorders.
Who should consider this trial
Good fit: Ideal candidates are individuals diagnosed with idiopathic REM sleep behavior disorder who have not yet developed Parkinson's disease or other neurodegenerative disorders.
Not a fit: Patients with a known diagnosis of Parkinson's disease or other neurodegenerative disorders will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a reliable method for early identification of patients at risk for Parkinson's disease and related disorders.
How similar studies have performed: Other studies have shown promise in using artificial intelligence for predictive modeling in neurodegenerative diseases, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Confirmed clinical iRBD diagnosis by movement disorder specialists according to the International Classification of Sleep Disorders 2. Written informed consent Exclusion Criteria: 1. Known diagnosis of PD or other neurodegenerative disorder 2. Unequivocal signs of parkinsonism on examination 3. Narcolepsy or other known causes of RBD 4. Moderate to severe obstructive sleep apnea 5. Abnormal neurological or MRI examination
Where this trial is running
Bern
- Inselspital, University Clinic for Nuclear Medicine — Bern, Switzerland (Recruiting)
Study contacts
- Principal investigator: Kuanggyu Shi, Prof. Dr. ing. — University Bern, Inselspital, Center for Artificial Intelligence in Medicine
- Study coordinator: Axel Rominger, Prof. Dr. med.
- Email: axel.rominger@insel.ch
- Phone: +41 316322610
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.